S
0QN1
vs
S
Swiss Market Index
Over the past 12 months, 0QN1 has outperformed Swiss Market Index, delivering a return of +22% compared to the Swiss Market Index's +14% growth.
Stocks Performance
0QN1 vs Swiss Market Index
Performance Gap
0QN1 vs Swiss Market Index
Performance By Year
0QN1 vs Swiss Market Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Santhera Pharmaceuticals Holding AG
Glance View
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. The company is headquartered in Pratteln, Basel-Landschaft. The company went IPO on 2006-11-03. The firm is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
